At the end of all this, a final figure is generated – the Incremental Cost Effectiveness Ratio, which is the cost of one extra quality-adjusted life year which the new treatment achieves when compared to the best current alternative. If this is more than £30,000 NICE will not approve the use of the drug by the NHS, although exceptions will sometimes be made for patients dying from rare cancers.
